Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Welcome and Introduction to Vi3C

Advertisement

Advertisement




May
08
Today In Oncology
Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer PROs in TOPAZ-1
Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer
Local Recurrence of Endometrial Cancer Radiotherapy With or Without Cisplatin
Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers
Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside